Adicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private Placement and Exercise in Full of t...
Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for cancer and other diseases, today announced the closing of an
underwritten public offering of 10,575,513 shares of its common
stock, including the exercise in full by the underwriters of their
option to purchase up to an additional 1,344,743 shares of common
stock at a public offering price of $13.00 per share. The aggregate
gross proceeds from the offering, before deducting underwriting
discounts and commissions and offering expenses were approximately
$137.5 million. All of the shares in the offering are to be sold by
In connection with the offering, Adicet entered into a stock
purchase agreement with certain existing investors for $15.0
million of shares of its common stock at a price per share equal to
the public offering price, with an initial closing for certain
investors held simultaneously with the closing of the offering and
a subsequent closing for certain additional investors.
Guggenheim Securities, LLC acted as book-running manager for the
offering. Canaccord Genuity LLC, Wedbush Securities Inc. and JMP
Securities LLC acted as co-managers for the offering.
The shares are being offered by Adicet pursuant to a shelf
registration statement that was previously filed with, and
subsequently declared effective on February 12, 2019 by, the U.S.
Securities and Exchange Commission (SEC). A final prospectus
supplement relating to and describing the terms of the offering was
filed with the SEC on February 11, 2021. Copies of the final
prospectus supplement and the accompanying prospectus relating to
the offered securities may be obtained from Guggenheim Securities,
LLC, Attention: Equity Syndicate Department, 330 Madison Avenue,
8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or
by email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Adicet Bio, Inc. is a biotechnology company discovering and
developing allogeneic gamma delta T cell therapies for cancer and
other diseases. Adicet is advancing a pipeline of “off-the-shelf”
gamma delta T cells, engineered with chimeric antigen receptors and
T cell receptor-like antibodies to enhance selective tumor
targeting, facilitate innate and adaptive anti-tumor immune
response, and improve persistence for durable activity in
Inc.Investor and Media ContactsAnne
Janhavi MohiteStern Investor Relations, Inc.212-362-1200
Source: Adicet Bio, Inc.